Core Insights - Amphastar Pharmaceuticals reported third-quarter 2025 financial results that exceeded analyst expectations, leading to a 4.9% increase in share price during the afternoon session [1][2] - The company achieved revenue of $191.8 million, surpassing the consensus estimate of $184.5 million, and adjusted earnings per share of $0.93, exceeding expectations of $0.83 [2] - Despite flat revenue compared to the previous year and a decline in operating margins, the market reacted positively due to the company's ability to outperform forecasts [2] Financial Performance - Revenue for the third quarter was $191.8 million, which is flat year-over-year but above Wall Street's estimate [2] - Adjusted earnings per share were reported at $0.93, beating the expected $0.83 [2] - The stock price settled at $24.95, reflecting a 3% increase from the previous close after an initial surge [2] Market Reaction - Amphastar's shares have shown volatility, with 12 movements greater than 5% in the past year, indicating that the market finds the recent news significant but not fundamentally altering its view of the company [4] - The stock has decreased by 31.4% since the beginning of the year and is trading 48.6% below its 52-week high of $48.57 from November 2024 [6] - An investment of $1,000 in Amphastar shares five years ago would now be worth $1,312, reflecting a modest growth over the period [6]

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.96 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +20.78%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.71 per share when it actually produced earnings of $0.85, delivering a surprise of +19.72%.Over ...

Financial Data and Key Metrics Changes - For Q3 2025, the company reported net revenues of $191.8 million, a slight increase from $191.2 million in the previous year [10] - GAAP net income was $17.3 million, or $0.37 per diluted share, down from $40.4 million, or $0.78 per diluted share in Q3 2024 [15] - Adjusted net income decreased to $44.6 million, or $0.93 per diluted share, compared to $49.6 million, or $0.96 per diluted share in the prior year [15] - Gross margins declined to 51.4% from 53.3% in the previous year's period [12] Business Line Data and Key Metrics Changes - Vaccimi sales reached $53.6 million, up 14% year-over-year from $40.4 million [10][11] - Primatene Mist sales increased by 11% to $28.8 million from $26.1 million [10] - Glucagon injection sales fell 49% to $13.6 million due to decreased unit volumes and increased competition [11] - Epinephrine sales decreased 12% to $18.8 million, while lidocaine sales dropped 19% to $12.9 million [11] - Other pharmaceutical product sales rose to $64.1 million from $58.3 million, driven by increased albuterol sales and the launch of iron sucrose injection [11] Market Data and Key Metrics Changes - The company is positioned to capture a combined market opportunity of over $60 billion with its newly added assets in oncology and ophthalmology [5] - The market for wet age-related macular degeneration and diabetic macular edema is valued at $9.4 billion [5] Company Strategy and Development Direction - The company is focused on a vertically integrated strategy and expanding its proprietary pipeline, aiming for proprietary products to comprise 50% of its pipeline by 2026 [6] - A significant expansion in US manufacturing capacity is planned to quadruple production at its Rancho Cucamonga headquarters [5] - The company is advancing its regulatory initiatives, including the FDA approval of iron sucrose injection, which is now commercially available [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving flat year-over-year revenue for the current year, with expectations of high single-digit to low double-digit growth for the next year [20] - The company is optimistic about the long-term growth potential of Vaccimi, forecasting peak sales of $250 million to $275 million [44] Other Important Information - The company has entered into an exclusive in-licensing agreement with Nanjing Anji Biotechnology for three early-stage peptide candidates [4] - A litigation provision related to a recent jury verdict has significantly impacted general and administrative expenses [13] Q&A Session Summary Question: Updated thoughts on year-over-year top line and growth for next year - Management believes they can achieve flat revenue this year and anticipates high single-digit to low double-digit growth next year [20] Question: Opportunity size for iron sucrose - The current run rate for iron sucrose is approximately $2.4 million, which is expected to stabilize [20] Question: Updates on AMP007 and FDA communication - Engagement with the FDA continues, with slight delays in interactions but no missed dates reported [23] Question: Competitive dynamics for generic Venofer - The company aims to launch iron sucrose with a profitable price portfolio and is adjusting guidance for next year based on risk [27] Question: Licensing with Nanjing Anji and business development appetite - The company is excited about the new peptide candidates and is looking for either commercialized or late-stage R&D assets in future deals [32] Question: Competitive landscape for insulin aspart - The company expects to face three or more competitors in the insulin aspart market but believes it will still be a significant opportunity [35] Question: Competition for Primatene Mist post-patent expiration - Management does not anticipate immediate competition for Primatene Mist but acknowledges the potential for generic entries [36] Question: Development path for in-licensed products - The new chemical products will follow the standard regulatory pathway, with some expected to have shorter paths to market [39]

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $191.8 million. Its non-GAAP profit of $0.93 per share was 12.7% above analysts’ consensus estimates. Is now the time to buy Amphastar Pharmaceuticals? Find out in our full research report. Amphastar Pharmaceuticals (AMPH) Q3 CY2025 Highlights: Revenue: $191.8 million vs analyst estimates of $184.5 million (flat year on year, 4% beat) Adjust ...

Corporate Presentation November 2025 Highly Purified Peptide/Protein Proprietary Injectables Inhalation Intranasal Biosimilar Interchangeable Complex Generic Combination Products Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements, of Amphastar Pharmaceuticals, Inc. ("Amphastar", "we". "our" and that are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statem ...

FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 AMPHASTAR PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 33-0702205 (Sta ...

RANCHO CUCAMONGA, CA – November 6, 2025 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today reported results for the three months ended September 30, 2025. "Amphastar delivered another strong quarter, led by double-digit growth from BAQSIMI®, which achieved a 14% increase in revenue compared to the same period last ...

The market expects Amphastar Pharmaceuticals (AMPH) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected ...

Core Viewpoint - Amphastar Pharmaceuticals, Inc. will announce its third quarter financial results for 2025 on November 6, 2025, after market close [1] Financial Results Announcement - The financial results will cover the period ended September 30, 2025 [1] - A conference call to discuss the results is scheduled for 2:00 p.m. Pacific Time on the same day [1]

Core Insights - The article emphasizes the importance of the Zacks Rank system and Style Scores in identifying strong investment opportunities, particularly in value investing [1][3] Company Overview - Amphastar Pharmaceuticals (AMPH) is highlighted as a strong value investment, currently holding a Zacks Rank 1 (Strong Buy) and an A for Value [4] - The stock has a P/E ratio of 7.81, significantly lower than the industry average of 11.72, indicating potential undervaluation [4] - AMPH's Forward P/E has fluctuated between 6.09 and 12.02 over the past year, with a median of 8.31 [4] Valuation Metrics - The P/B ratio for AMPH is 1.72, compared to the industry average of 3.63, suggesting it is undervalued relative to its book value [5] - AMPH's P/S ratio stands at 1.49, while the industry average is 3.6, reinforcing the notion of undervaluation [6] - The P/CF ratio for AMPH is 6.90, significantly lower than the industry average of 19.14, indicating a strong cash flow outlook [7] Investment Outlook - The combination of these valuation metrics suggests that Amphastar Pharmaceuticals is likely undervalued, making it an attractive option for value investors [8]